PURE Bioscience, Inc. (PURE)
| Previous Close | 0.0680 |
| Open | 0.0750 |
| Bid | 0.0650 x 0 |
| Ask | 0.0750 x 0 |
| Day's Range | 0.0750 - 0.0750 |
| 52 Week Range | 0.0600 - 0.1700 |
| Volume | |
| Avg. Volume | 23,666 |
| Market Cap | 8.389M |
| Beta (5Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings Date | Jun 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WirePURE Bioscience to Unveil its Newest Food Safety Solutions at the Annual International Association for Food Protection Meeting
EL CAJON, Calif., July 02, 2024--PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, is set to unveil its newest food safety solutions at the 2024 International Association for Food Protection (IAFP) show in Long Beach, California on July 14th-17th, 2024.
Business WirePURE Bioscience Announces an International Supply and License Agreement with AgroVet Alliance
EL CAJON, Calif., June 18, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, and AgroVet Alliance, FZE ("AVA"), have entered into a multi-year international supply and license agreement for the purchase and selling of SDC products under special terms and conditions.
Business WirePURE Bioscience Reports Fiscal Third Quarter 2024 Financial Results
EL CAJON, Calif., June 14, 2024--PURE Bioscience, Inc. (OTCQB: PURE) ("PURE," the "Company" or "we"), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal third quarter ended April 30, 2024.
